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Abstract
Background: In the present study, the methanol extracts from the leaves, as well as compounds namely sigmoidin
I (1), atalantoflavone (2), bidwillon A (3), neocyclomorusin (4), 6α-hydroxyphaseollidin (5) and neobavaisoflavone
(6) (from the bark extract) were tested for their activities against a panel of Gram-negative bacteria including
multi-drug resistant (MDR) phenotypes.
Methods: Broth microdilution method was used to determine the minimum inhibitory concentrations (MICs) and
the minimum bactericidal concentrations (MBCs) of the extracts as well as compounds 1–6.
Results: The MIC results indicated that the crude extracts from the leaves and bark of this plant were able to inhibit
the growth of 96.3 % of the 27 tested bacteria. Compounds 2–6 displayed selective activities, their inhibitory effects
being obtained on 8.3 %, 41.7 %, 58.3 %, 58.3 % and 66.7 % of tested bacteria respectively for 2, 3, 5, 6 and 4. The
lowest MIC value of 8 μg/mL was obtained with 6 against Escherichia coli ATCC8739, Enterobacter cloacae ECCI69,
Klebsiella pneumoniae KP55, Providencia stuartii NAE16 and Pseudomonas aeruginosa PA01.
Conclusion: The present study demonstrates that Erythrina sigmoidea is a potential source of antibacterial drugs to
fight against MDR bacteria. Neobavaisoflavone (6) is the main antibacterial consituents of the bark crude extract.
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Background
Medicinal plants have been used since ancient times
in the management of human including microbial
infections. Approximately 60 % of world’s population
still relies on medicinal plants for their primary
healthcare [1]. The African mainland has between
40,000-60,000 plant species, of which approximately
35,000 are endemic [2, 3]. Cameroon has a rich bio-
diversity, with about 8,620 plants species [4]. Several
Camerooninan medicinal plants were previously reported
for their antibacterial activities against multi-drug resistant
Gram-negative bacteria [5–8]. Some of the them include
Beilschmiedia cinnamomea and Echinops giganteus [5],
Beilschmiedia obscura, Pachypodanthium staudtii and
Peperomia fernandopoiana [9] or Capsicum frutescens
[10]. The antimicrobial activities of many secondary
metabolites from Cameroonian plants were also reported
[11, 12]. In our continuing search of new herbal drug from
the Cameroon flora, the present study was designed to
demonstrate the antibacterial activity of the extracts and
compounds from Erythrina sigmoidea Hua (Fabaceae).
Erythrina sigmoidea is a tree of up to 6 m high, with stems
armed with stout found in Senegal, Nigeria, Cameroon,
Chad and Central African Republic [13]. The plant is
traditionally used as antidotes (venomous stings, bites,
etc.), diuretic, febrifuge and to treat arthritis, rheuma-
tism, pulmonary troubles, stomach troubles, infectious
diseases and kidney diseases [13]. In the Western
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Region of Cameroon, the aqueous extracts from leaves,
bark and roots are used to treat gastrointestinal infections,
venereal diseases and leprosy [14]. Previously phytochem-
ical study this plant led to the isolation of sigmoidin I (1),
atalantoflavone (2), bidwillon A (3), neocyclomorusin (4),
6α-hydroxyphaseollidin (5), and neobavaisoflavone (6)
[15]. They displayed good cytotoxicity towards drug-
sensitive and drug resistant cancer cell line [15]. In
addition, they showed low cytotoxicity against the normal
AML12 hepatocytes [15].
Methods
Plant material and extraction
The leaves and bark of Erythrina sigmoidea (Fabaceae)
were collected in April 2013 in Bangangté (West Region
of Cameroon). The plant was identified by a botanist of
the National Herbarium in Yaoundé, Cameroon and
compared with voucher kept under the registration
number N°24470/HNC.
Antimicrobial assays
Chemicals for antimicrobial assay
Compounds isolated from the bark of Erythrina sigmoidea
included β- sigmoidin I (1), atalantoflavone (2), bidwillon A
(3), neocyclomorusin (4), 6α-hydroxyphaseollidin (5) and
neobavaisoflavone (6) (Fig. 1). Their isolation and identifica-
tion were previously reported [15]. Chloramphenicol ≥ 98 %
(Sigma-Aldrich, St. Quentin Fallavier, France) was used as
reference antibiotics (RA) against Gram-negative bacteria.
p-Iodonitrotetrazolium chloride ≥ 97 % (INT, Sigma-
Aldrich) was used as microbial growth indicator [16, 17].
Microbial strains and culture media
The studied microorganisms included sensitive and
resistant strains of Escherichia coli (ATCC8739, AG100,
AG100A, AG100ATET, AG102, MC4100, W3110),
Enterobacter aerogenes (ATCC13048, CM64, EA27,
EA289, EA294, EA298), Enterobacter cloacae (ECCI69,
BM47, BM67), Klebsiella pneumoniae (ATCC12296,
KP55, KP63, K24, K2), Providencia stuartii (NEA16,
ATCC29916, PS2636, PS299645) and Pseudemonas
aeruginosa (PA01, PA124) obtained clinically or from
the American Type Culture Collection. Their bacterial
features are summarized in Table 1. Nutrient agar was
used for the activation of the tested bacteria [18].
INT colorimetric assay for MIC and MBC determinations
MIC determinations on the tested bacteria were con-
ducted using rapid p-iodonitrotetrazolium chloride (INT)
colorimetric assay according to described methods [16]
with some modifications [19, 20]. The test samples and
chloramphenicol were first of all dissolved in DMSO/
Mueller Hinton Broth (MHB) or DMSO/7H9 broth. The
final concentration of DMSO was lower than 2.5 %
and does not affect the microbial growth [21, 22].
The 96- wells microplate were used and the inoculum
concentration was 1.5 × 106 CFU/mL [19, 20]. The
plates were incubated at 37 °C for 18 h. The assay
was repeated thrice. Wells containing adequate broth,
bacterial inoculum and DMSO to a final concentra-
tion of 2.5 % served as negative control. The MIC of
samples was detected after 18 h incubation at 37 °C,
following addition (40 μL) of 0.2 mg/mL of INT and
incubation at 37 °C for 30 min. Viable bacteria reduced
the yellow dye to a pink. MIC was defined as the sample
concentration that prevented the color change of the
medium and exhibited complete inhibition of microbial
growth [16]. The MBC was determined by adding 50 μL
aliquots of the preparations, which did not show any










Fig. 1 Chemical structures of the compounds isolated from Erythrina sigmoidea. sigmoidin I (1); atalantoflavone (2); bidwillon A (3); neocyclomorusin
(4); 6α-hydroxyphaseollidin (5); neobavaisoflavone (6)
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adequate broth. These preparations were incubated at
37 °C for 48 h. The MBC was regarded as the lowest
concentration of extract, which did not produce a color
change after addition of INT as mentioned above [19, 20].
Results and discussion
Compounds tested in this study included five isoflavo-
noids: atalantoflavone (2), bidwillon A (3), neocyclomor-
usin (4), 6α-hydroxyphaseollidin (5), neobavaisoflavone
(6) and one flavonoid: sigmoidin I (1) (Fig. 1). Their isola-
tion and identification from the bark of Erythrina sigmoi-
dea were previously reported [15]. These compounds as
well as the crude extracts from the leaves and bark of
Erythrina sigmoidea were tested for their antibacterial
activities on a panel bacterial strains and the results are
reported in Tables 2 and 3.
Results of the MIC determinations indicate that crude
extracts from leaves and bark of this plants were able to
Table 1 Bacterial strains used and their features
Strains Features and references
Escherichia coli
ATCC8739 Reference strain
AG100 Wild-type E. coli K-12 [34]
AG100A AG100 ΔacrAB::KANR [11, 34, 35]
AG100ATET ΔacrAB mutant AG100, with over-expressing acrF gene; TET
R [34]
AG102 ΔacrAB mutant AG100, owing acrF gene markedly over-expressed; TETR [12, 36]
MC4100 Wild type E. coli [37]
W3110 Wild type E. coli [37, 38]
Enterobacter aerogenes
ATCC13048 Reference strains
CM64 CHLR resistant variant obtained from ATCC13048 over-expressing
the AcrAB pump
[39]
EA27 Clinical MDR isolate exhibiting energy-dependent norfloxacin and
chloramphenicol efflux with KANR AMPR NALR STRR TETR
[40, 41]
EA289 KAN sensitive derivative of EA27 [42]
EA294 EA289 acrA::KANR [42]
EA298 EA 289 tolC::KANR [42]
Enterobacter cloacae
ECCI69 Clinical MDR isolates, CHLR [5]
BM47 Clinical MDR isolates, CHLR [5]
BM67 Clinical MDR isolates, CHLR [5]
Klebsiella pneumoniae
ATCC12296 Reference strains
KP55 Clinical MDR isolate, TETR, AMPR, ATMR, CEFR [43]
KP63 Clinical MDR isolate, TETR, CHLR, AMPR, ATMR [43]
K24 AcrAB-TolC, Laboratory collection of UNR-MD1, University of Marseille, France [5]
K2 AcrAB-TolC, Laboratory collection of UNR-MD1, University of Marseille, France [5]
Providencia stuartii [30]
NEA16 Clinical MDR isolate, AcrAB-TolC
ATCC29916 Clinical MDR isolate, AcrAB-TolC
PS2636 Clinical MDR isolate, AcrAB-TolC
PS299645 Clinical MDR isolate, AcrAB-TolC
Pseudemonas aeruginosa
PA 01 Reference strains
PA 124 MDR clinical isolate [44]
aAMP, ATMR, CEFR, CFTR, CHLR, FEPR, KANR, MOXR, STRR, TETR. Resistance to ampicillin, aztreonam, cephalothin, cefadroxil, chloramphenicol, cefepime, kanamycin,
moxalactam, streptomycin, and tetracycline; MDR : Multidrug resistant
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inhibit the growth of 26 of the 27 (96.3 %) tested Gram-
negative bacteria, and the obtained MIC values ranged
from 16 to 1024 μg/mL (Table 2). Compound 1 was not
active whilst 2–6 displayed selective activities (Table 3),
the MIC values below or equal to 512 μg/mL being
noted on 1/12 (8.3 %), 5/12 (41.7 %), 7/12 (58.3 %), 7/12
(58.3 %) and 8/12 (66.7 %) tested bacteria respectively
for 2, 3, 5, 6 and 4. The lowest MIC value of 16 μg/mL
for crude extracts was obtained with the bark extract
against Escherichia coli ATCC8739, Enterobacter aerogenes
EA294 and Klebsiella pneumoniae KP63. The corre-
sponding value for the tested compounds (8 μg/mL) was
obtained with 6 against E. coli ATCC8739, Enterobacter
cloacae ECCI69, K. pneumoniae KP55, Providencia stuartii
NAE16 and Pseudomonas aeruginosa PA01. The antimicro-
bial activity of a phytochemical (crude extract) has been
defined as significant when MIC is below 100 μg/mL,
moderate when 100 μg/mL <MIC < 625 μg/mL or low
Table 2 MICs and MBC (μg/mL) of the crude extracts from Erythrina sigmoidea and chlroramphenicol on the panel of tested bacteria
Bacterial strains Tested plant samples, MIC and MBC (μg/ml) and ratio MBC/MIC
Erythrina sigmoidea leaves extract Erythrina sigmoidea bark extract Chloramphenicol
MIC MBC MBC/MIC MIC MBC MBC/MIC MIC MBC MBC/MIC
Escherichia coli
ATCC8739 64 64 1 16 64 4 4 64 16
AG100 32 256 8 32 128 4 8 >512 na
AG100A 512 1024 2 256 1024 4 4 >512 na
AG100ATET 1024 1024 1 256 512 2 32 >512 na
AG102 512 1024 2 128 1024 8 8 >512 na
MC4100 1024 1024 1 512 512 1 32 >512 na
W3110 512 512 1 512 512 1 8 >512 na
Enterobacter aerogenes
ATCC13048 128 256 2 128 1024 8 16 128 8
CM64 1024 >1024 na 1024 na 512 >512 na
EA27 256 256 1 64 128 2 128 >512 na
EA289 1024 >1024 na 512 >1024 na 512 >512 na
EA298 512 512 1 512 1024 2 256 >512 na
EA294 64 512 8 16 128 8 4 32 8
Enterobacter cloacae
ECCI69 1024 >1024 na 1024 >1024 na 256 >512 na
BM47 1024 1024 1 1024 1024 1 512 >512 na
BM67 1024 >1024 na 1024 1024 1 256 >512 na
Klebsiella pneumoniae
ATCC11296 256 256 1 64 512 8 16 128 8
KP55 512 >1024 na 256 >1024 na 64 256 4
KP63 128 >1024 na 16 128 8 128 >512 na
K24 256 512 2 128 >1024 na 16 >512 na
K2 128 1024 8 64 512 8 16 256
Providencia stuartii
ATCC29916 128 >1024 na 32 128 4 8 128 16
NAE16 128 128 1 32 >1024 na 8 256 32
PS2636 1024 >1024 na 1024 1024 1 64 >512 na
PS299645 512 1024 2 64 128 2 32 >512 na
Pseudomonas aeruginosa
PA01 1024 1024 1 256 256 1 16 256 8
PA124 >1024 >1024 na >1024 >1024 na 64 |256 4
na: not applicable
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Table 3 MICs and MBC of compounds from the bark of Erythrina sigmoidea on selected bacteria
Bacterial strains Tested compounds, MIC and MBC (μg/ml) and ratio MBC/MIC
1 2 3 4 5 6
MIC MBC MBC/MIC MIC MBC MBC/MIC MIC MBC MBC/MIC MIC MBC MBC/MIC MIC MBC MBC/MIC MIC MBC MBC/MIC
Escherichia coli
ATCC8739 - - na - - na 512 - na 256 - na 512 - na 8 - na
AG100ATET - - na 128 - na - - na 256 - na 512 - na 32 - na
AG102 - - na - - na 512 - na 128 512 4 512 512 1 - - na
Enterobacter aerogenes
ATCC13048 - - na - - na - - na 512 - na - - na - - na
EA289 - - na - - na - - na - - na - - na - - na
Enterobacter cloacae
ECCI69 - - na - - na - - na - - na - - na 8 512 64
Klebsiella pneumoniae
ATCC11296 - - na - - na - - na - - - na - - na
KP55 - - na - - na 256 - na 256 512 2 512 - na 8 - na
Providencia stuartii
ATCC29916 - - na - - na 256 - na 256 - na 512 - na - - na
NAE16 - - na - - na - - na 256 - na 512 - na 8 - na
Pseudomonas aeruginosa
PA01 - - na - - na 256 - na 256 - na 512 - na 8 - na
PA124 - - na - - na - - na - - na - - na 256 - na


















when MIC > 625 μg/mL [4, 23]. On this basis, the crude
extracts from Erythrina sigmoidea could be considered as
promising herbal drug > In fact, MIC values below
100 μg/mL were obtained with leaves and bark extracts
respectively against 3/27 (11.1 %) and 10/27 (37.0 %)
tested bacteria. Compound 6 can also be considered as a
good antimicrobial agent, as MIC values below 10 μg/mL
were obtained on 5/12 (41.7 %) tested bacteria. Interest-
ingly, the bark extract was more active (lower MIC value)
than chloramphenicol on some MDR strains such as E.
aerogenes EA27, K. pneumoniae KP63, highlighting its
good antimicrobial potency. Minimal bactericidal concen-
tration (MBC) values below or equal to 1024 μg/mL were
also obtained on 18/27 (66.7 %) and 20/27 (74.1 %) tested
bacterial strains respectively for leaves and bark extracts.
Data from Tables 2 and 3 indicated that some MBC/MIC
ratios were below 4, indicating that the studied extracts
exerted bactericidal effects on certain Gram negative
bacteria [24–26]. However, a keen look of the MICs and
MBCs of compounds indicated that they rather exerted
bacteriostatic effects (MBC/MIC > 4) [24–26]. It should
be noted that the antibacterial spectra of compounds were
lower than that of the bark extract. This suggested that a
possible synergistic effect between the constituents of this
extract could be expected. It should also be noted that the
bark extract was not active on the resistant P. aeruginosa
PA124 strains contrary to the isolated compound 6. This
can either be due to the fact that this active compound (6)
is less concentrated in the initial crude extract or to the
possible interactions with other constituent. Regarding the
clinical involvement of MDR bacteria in treatment failures
[11, 12, 27, 28], the antibacterial activity of the crude ex-
tracts as well as that of compound 6 could be considered
promising. Pseudomonas aeruginosa is an important
nosocomial pathogen, highly resistant to clinically used
antibiotics, leading to substantial morbidity and mortality
[29]. MDR Enterobacteriaceae, including K. pneumoniae,
E. aerogenes, E.cloacae and P. stuartii and E. coli have also
been classified as antimicrobial-resistant organisms of
concern in healthcare facilities [11, 12, 30].
To the best of our knowledge, the antibacterial
activity of the crude extracts from the Erythrina
sigmoidea as well as compounds 2–6 against MDR
bacteria is being reported for the first time. However,
the antibacterial activities of compounds belonging to
the classes flavonoids and isoflavonoids are well
known [31]. In addition, a preliminary antibacterial
study of flavonoids from the stem bark of Erythrina
burttii showed that bidwillon A was active against E. coli
and Staphylococcus aureus [32]. Neobavaisoflavone also
displayed antifungal activity against Aspergillus fumigatus
and Cryptococcus neoformans [33]. The present study
provides additional information on the antimicrobial
potency of neobavaisoflavone (6).
Conclusions
The results of the present study are interesting, taking in
account the medical importance of the studied
microorganisms. These data provided evidence that
the crude extracts from Erythrina sigmoidea as well
as some of its constituents, and mostly neobavaisofla-
vone (6) could be potential antimicrobial drugs to
fight MDR bacterial infections.
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